Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE
Ultragenyx Pharmaceutical — Shareholder Meeting (April 2026)
7 slides from Ultragenyx Pharmaceutical's shareholder meeting presentation, Apr 30, 2026
Slide 1: 2026 Annual Meeting of Stockholders – Definitive Additional Proxy Soliciting Materials
Ultragenyx logo Ultragenyx Pharmaceutical Inc. 2026 Annual Meeting of Stockholders | May 14, 2026 Definitive Additional Proxy Soliciting Materials This presentation is filed as definitive additional proxy soliciting materials pursuant to Section 14(a) of the Securities Exchange Act of 1934. It suppl
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, e
Slide 3: Proposals for the 2026 Annual Meeting of Stockholders
Proposals for the 2026 Annual Meeting of Stockholders On March 27, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”, “we”, “our”, “Ultragenyx”) filed a definitive proxy statement (the “Proxy Statement”) with the SEC in connection with our 2026 Annual Meeting of Stockholders (“Annual Meeting”) to
Slide 4: Supplemental Information regarding Proposal 2 (the Plan, including the Share Increase)
Ultragenyx logo Supplemental Information regarding Proposal 2 (the Third A&R Incentive Plan, including the Share Increase) © 2026 Ultragenyx Pharmaceutical Inc. | Confidential and Proprietary
Slide 5: Key Reasons Why Stockholders Should Vote FOR the Plan and the Share Increase
• Key Reasons Why Stockholders Should Vote FOR the Third A&R Incentive Plan and the Share Increase Glass Lewis has recommended FOR this proposal. ISS has recommended AGAINST this proposal. We respectfully disagree with ISS’s recommendation and believe the plan is in our stockholders’ best interests
Slide 6: Disciplined Management of our Burn Rate
• Disciplined Management of our Burn Rate We carefully and thoughtfully manage our equity award use, balancing attraction, retention and incentivization of our employees against dilution and burn rate considerations • Recent actions we have taken to manage the burn rate and overhang effectively whil
Slide 7: Governance Best Practices
Governance Best Practices The Third A&R Incentive Plan includes numerous provisions that protect stockholders and reflect corporate governance best practices X No evergreen provision X No repricing or reloading of options without stockholder approval X No dividends on unvested awards X No liberal sh
Ultragenyx Pharmaceutical — Shareholder Meeting (April 2026) on 6ix